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Background. Imatinib, a tyrosine kinase inhibitor, has
been shown to restore blood–brain barrier integrity
and reduce infarct size, haemorrhagic transforma-
tion and cerebral oedema in stroke models treated
with tissue plasminogen activator. We evaluated
the safety of imatinib, based on clinical and neu-
roradiological data, and its potential influence on
neurological and functional outcomes.
Methods. A phase II randomized trial was performed
in patients with acute ischaemic stroke treated
with intravenous thrombolysis. A total of 60
patients were randomly assigned to four groups
[3 (active): 1 (control)]; the active treatment groups
received oral imatinib for 6 days at three dose
levels (400, 600 and 800 mg). Primary outcome
was any adverse event; secondary outcomes were
haemorrhagic transformation, cerebral oedema,
neurological severity on the National Institutes of
Health Stroke Scale (NIHSS) at 7 days and at
3 months and functional outcomes on the modified
Rankin scale (mRS).
Results. Four serious adverse events were reported,
which resulted in three deaths (one in the control
group and two in the 400-mg dose group; one
patient in the latter group did not receive active
treatment and the other received two doses). Non-
serious adverse events were mostly mild, resulting
in full recovery. Imatinib ameliorated neurological
outcomes with an improvement of 0.6 NIHSS
points per 100 mg imatinib (P = 0.02). For the
800-mg group, the mean unadjusted and adjusted
NIHSS improvements were 4 (P = 0.037) and 5
points (P = 0.012), respectively, versus controls.
Functional independence (mRS 0–2) increased by
18% versus controls (61 vs. 79; P = 0.296).
Conclusion. This phase II study showed that imatinib
is safe and tolerable and may reduce neurological
disability in patients treated with intravenous
thrombolysis after ischaemic stroke. A confirma-
tory randomized trial is currently underway.
Keywords: cerebral infarct, cerebral oedema, ima-
tinib, intracerebral haemorrhage, stroke, throm-
bolysis.
Introduction
Disruption of the blood–brain barrier (BBB) is a
critical pathophysiological event following cerebral
ischaemia [1–5], which may play a significant role
in haemorrhagic transformation and cerebral
oedema after treatment with tissue plasminogen
activator (tPA) [6, 7]. Moreover, a leaky BBB may
expose ischaemic tissue to infiltrating leucocytes
[8]. Severe vascular disruption in ischaemia is
associated with severe tissue injury [9]. Imatinib, a
tyrosine kinase inhibitor, can restore the integrity
of the BBB by blocking the signalling of platelet-
derived growth factor alpha (PDGF-alpha)
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receptors on perivascular astrocytes [10]. PDGF-
alpha receptors open the BBB after tPA-mediated
activation of the latent form of PDGF subtype CC
(PDGF-CC) [7, 11, 12]. Elevated plasma levels of
PDGF-CC are associated with haemorrhagic trans-
formation after treatment with tPA in ischaemic
stroke patients [13]. In experimental stroke mod-
els, treatment with imatinib decreases BBB per-
meability, lowers the risk of haemorrhagic
transformation and cerebral oedema and reduces
infarct size [10, 14].
Despite intravenous thrombolysis (IVT) [15–23]
and mechanical thrombectomy [24–28], up to
40% of patients are still functionally dependent or
dead at follow-up [29]. Only a minority of all
ischaemic stroke patients can be treated by reper-
fusion therapies because of the short time window
available for treatment, contraindications and risk
of haemorrhagic transformation.
The main aim of this study was to evaluate the
safety and tolerability of imatinib amongst ischae-
mic stroke patients treated with IVT. Secondary
aims were to determine the effect of imatinib on
haemorrhagic transformation, cerebral oedema
and neurological and functional outcomes.
Methods
Study design
I-Stroke was a prospective, randomized, open-
label, blinded end-point evaluation (PROBE), dose
escalation, regional multicentre clinical trial for
patients with acute ischaemic stroke who were
treated with IVT. After providing informed consent,
a total of 60 patients were randomly assigned [3
(active): 1 (control); using the web-based system
Viedoc] within 1 h after the termination of reper-
fusion treatment, with the aim of creating four
groups of equal size (n = 15 each), in three treat-
ment phases (n = 20 in each phase). The effects of
imatinib were tested at a daily dose of 400 mg (low
dose) in the first phase, at 600 mg (medium dose)
in the second phase and at 800 mg (high dose) in
the third phase. Each dose-increase phase was
preceded by clearance by an independent safety
committee based on evaluation of the serious and
nonserious adverse events. In case of a serious
adverse event during the third phase of the study
with high-dose imatinib, the independent safety
committee would have been involved but this did
not occur. All patients received IVT in agreement
with the accepted indications (Appendix 1).
Mechanical thrombectomy was performed in
patients with large artery occlusion who satisfied
the local criteria for intervention (Appendix 2).
The study protocol was approved by the Ethics
Committee of Karolinska Institutet and by the
Medical Products Agency of Sweden. The study
was registered with the European Clinical Trials
Database (EUDRA CT NR 2010-019014-25).
Patients and participating centres
The study was conducted at five centres in Stock-
holm County. Patients for whom mechanical
thrombectomy was considered had IVT initiated
at the local hospital and were then transferred to
Karolinska University Hospital at Solna. Patients
were 18–85 years old, with acute ischaemic stroke
onset causing a neurological deficit of 7–25 points
on the National Institutes of Health Stroke Scale
(NIHSS). A comprehensive list of exclusion criteria
is shown in Appendix 3.
Treatment
If allocated to the active treatment group, ima-
tinib was administered orally as soon as possible
after randomization (day 0) as tablets correspond-
ing to doses of 400, 600 or 800 mg, depending on
the phase of the study. From day 1 to day 5,
tablets were given each morning, except at the
highest dose level (800 mg) where tablets of
400 mg were given twice daily (morning and
evening).
Outcome measures
Primary outcome
The primary outcome of this study was any serious
or nonserious adverse event. The classification of
adverse events, severity and likelihood of relation
to treatment and clinical course was the local
investigator’s responsibility and was documented
in the case record form.
Secondary outcomes
In this study, secondary outcomes were the occur-
rence and severity of haemorrhagic transforma-
tion, cerebral oedema and infarct volume,
neurological outcomes as measured by the NIHSS
score and functional outcomes as measured by the
modified Rankin scale (mRS) score at 3 months.
The evaluation of infarct volume will be addressed
in a future publication.
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Clinical and radiological assessments
The NIHSS score was determined before IVT, at the
start of study treatment (baseline), after 2 h (day
0), on day 1 and then daily until day 7. Adverse
events were assessed daily from day 0 to day 7, and
at 3 months. Blinded evaluations of the NIHSS and
mRS scores were performed at 3 months at a
different hospital from the one responsible for the
acute treatment.
Computer tomography (CT) scans were performed
at baseline, 24 h (accepted interval 22–36 h) and,
optionally, at 7 days. Magnetic resonance imaging
(MRI) was performed at 24 h (accepted interval as
for CT) and at 7 days. CT and MRI examinations
were evaluated blindly by two experienced neuro-
radiologists to reach a consensus.
Definitions of haemorrhagic transformation, such
as haemorrhagic infarcts and intracerebral
(parenchymatous) haemorrhages and cerebral
oedema, have been described previously [17] (Data
S1).
Statistical analyses
Descriptive statistics for baseline, demographic
and imaging data were used to compare the differ-
ent treatment groups. Proportions were calculated
for categorical values, dividing the number of
events by the total number (excluding missing/
unknown values). Median values were calculated
for continuous variables and were compared using
a median regression. For the calculation of differ-
ences between proportions, we used Fisher’s exact
test. Potential associations between adverse events
and treatment groups were analysed using Fisher’s
exact test. The comparisons for creatinine, ALAT,
ASAT and total white blood cell count were made
using a two-sample t-test.
To analyse whether imatinib had any effect on the
NIHSS score, the dose of imatinib was treated both
as a categorical and a continuous variable. When
looking at separate time-points, a linear regression
with robust standard errors was used whilst
adjusting for thrombectomy status. When consid-
ering the mean effect over the entire time course, a
linear mixed model was used with a random
intercept and adjustment for thrombectomy status
using robust standard errors and allowing the
residuals to have an autoregressive 1 (AR1) corre-
lation within individuals. The choice to use AR1
correlation was made by comparing the Akaike
information criterion to a model without AR1
correlation. To model the median effect over the
entire time course, we used a median regression
with cluster robust standard errors [30]. Because
of some missing NIHSS values, multiple imputa-
tions [31] were used.
When comparing the mean percentage NIHSS
change from baseline, we used a linear regression
adjusted for thrombectomy status with bootstrap
confidence intervals. The shift analysis of the mRS
after 90 days was conducted using three separate
Mann–Whitney U-tests (comparing each imatinib
group to the control). The association between
treatment groups and functional independence
was analysed using logistic regression. Statistical
analyses were performed using STATA V.13 software
(StataCorp LP, College Station, TX, USA).
Results
Patient characteristics
Sixty patients were recruited between February
2011 and November 2014 (20 patients for each
dose level). In phase I, 15 patients were randomized
to low dose and five to control, in phase II, 14
patients to medium dose and six to control and in
phase III, 14 patients to high dose and six to
control. Baseline characteristics are shown in
Table 1. All patients were included in the safety
analysis (intention to treat). The remaining analy-
ses were performed, according to actual treatment
(per protocol) (Fig. 1).
Treatment
The median time from stroke onset to IVT for all
participants (n = 60) was 86 min (range 35–
269 min). For patients treated with mechanical
thrombectomy, the median time from onset to the
end of the intervention was 290 min (range 145–
465 min; exact time missing for three partici-
pants). For patients allocated to imatinib (n = 41),
the median time from stroke onset to the first dose
of imatinib was 240 min (range 75–714 min).
Safety analysis: mortality
Three patients died during the study period. One
patient, allocated to the low-dose group but not
receiving active treatment, died because of a
recurrent stroke. One control patient died because
of an infection. The third patient, who received one
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dose of 400 mg imatinib at the day of onset and on
day 1, died because of an infarct with intracerebral
haemorrhage and oedema. The investigator and
the independent safety committee found no likely
connection between the study treatment and the
patient’s clinical deterioration.
Safety analysis: adverse events
Serious adverse events
Four serious adverse events were reported, which
resulted in the death of three patients. The patient
in the control group who deteriorated because of
fever and infection also had a growing femoral
haematoma at the site of the femoral artery punc-
ture. There were no serious adverse events in the
medium- and high-dose groups.
Nonserious adverse events
In total, 118 nonserious adverse events were
reported in 41 patients (Table 2). Eleven cerebral
haemorrhagic events were reported in the medium-
dose group (10 were judged ‘unlikely’ to be related
to the imatinib treatment, and one was classified
‘possible’). Severity was mild, moderate and severe
in eight, two and one patients, respectively. There
were six reports of mild or moderate itching and
skin reactions in the high-dose group; the relation
to imatinib treatment was classified as ‘probable’,
‘possible’ or ‘expected’ in five cases and ‘unlikely’ in
one.
The severity of nonserious adverse events, plasma
concentrations of imatinib and laboratory values
are shown in the Data (S2, S3 and S4, respectively).
Haemorrhagic transformation and cerebral oedema
A total of 21 haemorrhagic infarctions (six HI1, 15
HI2) were observed in this study: six each in the
control, low-dose and medium-dose groups and
three in the high-dose group. Three intracerebral
haemorrhages were reported (two PH1, one PH2).
One PH1-type haemorrhage occurred in the control
group and one in the high-dose group; the PH2-
type haemorrhage occurred in the medium-dose
group.
In addition, four remote intracerebral haemor-
rhages of a milder grade (PHr1) were reported
(one each in the low- and medium-dose groups and
two in those receiving the high dose).
No haemorrhagic transformations (0 of 5) occurred
when imatinib treatment was initiated within 5 h
after stroke onset (Table 3) or when reperfusion
treatment (IVT alone or in combination with
thrombectomy) was completed within 4.5 h (0 of
6) in the high-dose group.
Results for cerebral oedema are available as Data
(S5). Overall, there were 33 cases of cerebral
oedema in the study: 28 mild (n = 7, 4, 7 and 10
in the control and low-, medium- and high-dose
groups, respectively), three moderate (n = 2 and 1
in the low- and medium-dose groups, respectively)
and two severe oedema (both in the control).
Table 1 Demographic and baseline data (intention-to-treat
population)
Control
Low
dose
Medium
dose
High
dose
Number of patients 17 15 14 14
Median age (years) 70 76 73 72
Male (%) 65 53 79 43
Hypertension (%) 76 73 64 50
Atrial fibrillation (%) 29 33 43 36
Diabetes (%) 18 20 7 7
Hyperlipidaemia (%) 35 20 29 36
Current smoker (%) 18 7 29 0
Previous smoker (%) 35 40 50 29
Previous stroke
>3 months (%)
12 7 0 7
Previous TIA (%) 12 13 7 0
Median baseline
NIHSS score
13 12 11 13
Intravenous
thrombolysis (%)
100 100 100 100
Intra-arterial
thrombolysis (%)
0 7 0 0
Mechanical
thrombectomy (%)
29 47 21 71
Stenting (%) 6 13 0 7
Aspirin (%) 31 47 36 21
Warfarin (%) 6 0 8 7
Oral antidiabetic
agent (%)
7 7 0 7
Insulin (%) 6 0 8 0
Statin (%) 50 20 21 21
TIA, transient ischaemic attack; NIHSS, National Insti-
tutes of Health Stroke Scale.
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Neurological outcomes
The mean unadjusted improvement in the NIHSS
score (Fig. 2) compared to controls over all time-
points after baseline was two points for the
low-dose group (P = 0.283), three points for the
medium-dose group (P = 0.084) and four points for
the high-dose group (P = 0.037). After adjustment
for thrombectomy, the corresponding mean
improvement compared to controls was two points
(P = 0.259), three points (P = 0.106) and five points
(P = 0.012).
For the three protocol-specified time-points, there
were significant improvements in the adjusted
mean NIHSS scores in patients treated with high
Allocated to Active treatment 
with imatinib (n = 43)
Low dose (n = 15) 
Medium dose (n = 14) 
High dose (n = 14) 
Randomized 3:1 (Active:Control)
Allocated to Control (n = 17)
Received imatinib (n = 39)
Low dose (n = 12)
Medium dose (n = 13)
High dose (n = 14)
Control group (n = 18)
Removed from per-protocol 
analysis (n = 3)
Reason: incomplete doses 
in Low dose group. 
Moved from Low dose 
to Control (n = 1)
Reason: did not receive 
any imatinib 
Moved from Medium 
to Low dose (n = 1)
Reason: received Low dose 
by oversight. 
60 patients treated with IV 
thrombolysis  4.5 hours were 
recruited between 
Per-protocol population (n = 57)
Intention-to-treat population (n = 60)
Feb 2011 and Nov 2014
Fig. 1 Overview of study
recruitment and populations
included in the intention-to-
treat (including all randomized
patients) and in per-protocol
analyses (including patients
treated according to protocol).
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Table 2 Nonserious adverse events
AEs Control (n = 17)
Low
dose (n = 15)
Medium
dose (n = 14)
High
dose (n = 14) Total (n = 60) P-value
Total number of AEs 25 19 44 30 118
Fever and infection 4 (6) 4 (7) 4 (5) 3 (3) 15 (21) 1
Itching and skin reaction 2 (2) 2 (2) 0 (0) 6 (6) 10 (10) 0.020
Cerebral bleeding 3 (3) 0 (0) 9 (11) 1 (1) 13 (15) <0.001
Arrhythmia and tachy/
bradycardia
3 (3) 1 (1) 3 (4) 2 (2) 9 (10) 0.483
Nausea and vomiting 0 (0) 1 (2) 2 (6) 4 (4) 7 (12) 0.063
Fall 1 (1) 0 (0) 2 (3) 1 (1) 4 (5) 0.528
Dyspnoea 2 (2) 0 (0) 1 (1) 1 (1) 4 (4) 0.780
Systemic bleeding 1 (3) 0 (0) 1 (1) 2 (3) 4 (7) 0.528
Fainting 0 (0) 0 (0) 0 (0) 2 (2) 2 (2) 0.103
Other 3 (5) 5 (7) 9 (13) 5 (7) 22 (32) 0.067
Data show number of patients with an event (total number of events) in the intention-to-treat population. AE, adverse
event.
Table 3 Haemorrhagic transformations
Any haemorrhagic transformation Control n = 18 Low dose n = 12 Medium dose n = 13 High dose n = 14
Stroke onset to imatinib treatment <5 h 4/8 4/9 0/5
Stroke onset to imatinib treatment ≥5 h 3/4 4/4 6/9
Stroke onset to end of reperfusion 0–4.5 h 5/16 5/9 6/11 0/6
Stroke onset to end of reperfusion >4.5 h 2/2 2/3 2/2 6/8
Data show number of patients with haemorrhagic transformations, relative to the total number of patients, in the per-
protocol population.
Fig. 2 National Institutes of
Health Stroke Scale (NIHSS)
score per treatment group and
time-point (solid lines, means;
dashed lines, 95% CIs; per-
protocol population).
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doses of imatinib compared to controls: five points
(5.28; 95% CI 9.60 to 0.96; P = 0.018) on day
1; 6 points (5.68; 95% CI 10.38 to 0.98;
P = 0.019) on day 7; and five points (4.81; 95%
CI 10.39 to 0.98; P = 0.019) at 3 months. There
were also significant improvements with the high
dose for all other individual time-points except 2 h.
When stratified by treatment with mechanical
thrombectomy, the improvement in the mean
NIHSS score between controls and the high-dose
group at day 7 was four points for patients who
underwent thrombectomy and five points for those
who did not. Compared to baseline, patients
treated with thrombectomy in the control group
(n = 6) showed an improvement in the mean NIHSS
of 10 points from baseline to 7 days (16–6). In the
high-dose group (n = 10), the corresponding
improvement was 12 points (14–2). For non-
thrombectomy patients, the corresponding
improvement was 5 points (11–6) in the control
group (n = 12) and 10 points (11–1) in the high-
dose group (n = 4).
Neurological outcomes improved with increasing
doses of imatinib throughout the study period. The
improvement in the mean unadjusted NIHSS score
compared to controls was 0.5 points per 100 mg
imatinib (0.5; 95% CI 0.98 to 0.02; P = 0.04).
After adjustment for thrombectomy, the
improvement was 0.6 score points per 100 mg
imatinib (0.59; 95% CI 1.08 to 0.09; P = 0.02).
Neurological outcome expressed as the median, as
improvement of ≥8 NIHSS points and as a percent-
age of the baseline value at different time-points is
shown in Data (S6).
Functional outcomes
Functional outcomes on the mRS are shown in
Fig. 3. Functional independence (mRS 0–2) was
observed in 61% of the control group and 72% of all
imatinib-treated patients. For the high-dose group,
there was an 18% absolute increase in the propor-
tion of functional independence and a higher odds
ratio adjusted for thrombectomy compared to con-
trol (2.33; 95% CI 0.48–11.44; P = 0.296).
Discussion
Treatment with all doses of imatinib daily for 6 days
in acute ischaemic stroke patients who received IVT
was safe and well tolerated. Although any efficacy
outcome should be interpreted with caution con-
sidering that the trial was a phase II study of limited
Fig. 3 Distribution of modified Rankin scale (mRS) scores in the per-protocol population. Scores ranged from 0 to 6: 0, no
symptoms; 1, no clinically significant disability; 2, slight disability (patients able to look after their own affairs without
assistance but unable to perform all previous activities); 3, moderate disability (patients require some help but able to walk
without assistance); 4, moderately severe disability (patients unable to attend to bodily needs or walk without assistance);
5, severe disability (patients require constant nursing care and attention); 6, death.
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size, the effect of imatinib on neurological outcome
increased dose dependently, with a 0.6-point
improvement in the NIHSS score per 100 mg ima-
tinib. Only the high-dose imatinib treatment
resulted in a statistically significant improvement
for the protocol-specified neurological outcomes at
day 7 and at 3 months compared to controls. The
improvement was consistent for the whole study
period and for each individual time-point later than
2 h after the initiation of thrombolysis. The neuro-
logical improvement with the high dose versus
control was clinically relevant, as it was comparable
to the effect of mechanical thrombectomy [24, 27].
This effect was added to the improvement achieved
by IVT and, when indicated, mechanical thrombec-
tomy. High-dose imatinib was also associated with
18% improvement of functional independency ver-
sus control, although these results should be
interpreted with extreme caution because of the
small numbers of patients in the study groups.
Imatinib is primarily used in the treatment of
haematological cancers with an acceptable rate of
adverse events in long-term follow-up [32] but has
not previously been used for the treatment of
stroke. For its usual indication, the dose is titrated
from a lower dose to an individually adapted level
up to a recommended maximum of 800 mg daily.
In this study, we started immediately with a dose of
400, 600 or 800 mg daily, with evaluation by an
independent safety committee between each dose
increase. We did not observe any serious adverse
events with imatinib treatment. Nonserious events
were mild or only moderately severe and tolerable.
Itching and skin reactions, and possibly also
nausea (results were nonsignificant), may be
related to treatment.
Although our findings on neurological outcome in
this clinical study are preliminary, they correlate
well with observations made in experimental stud-
ies [6–14]. There are several conceivable mecha-
nisms for an effect of imatinib, including the
restoration of the BBB with a reduction in the
subsequent inflammatory response, reduced
oedema and preserved nutritional supply to the
ischaemic area. The inflammatory response to
ischaemic injury includes the activation of micro-
glia, the production of pro-inflammatory mediators
and the infiltration of inflammatory cells, events
that contribute to ischaemic brain injury [8, 33].
The peak infiltration of inflammatory cells occurs
during the first days after acute stroke. Restriction
of the invasion of cells from the blood vessels to the
ischaemic brain may provide an explanation for an
effect of imatinib on the neurological outcomes.
An expected effect of BBB restoration would be a
reduced risk of haemorrhagic transformation after
IVT [21–23]. Interestingly, this increased risk of
haemorrhagic transformation observed before IVT
is greater in patients with higher levels of PDGF-CC
on admission and at 24 h after stroke [13]. In our
study, there were no marked differences between
the treatment groups regarding the total occur-
rence of haemorrhagic transformation. One expla-
nation may be that imatinib treatment was
administered too late to exert an overall influence
on the haemorrhage risk; of note, no haemorrhagic
transformation occurred in patients treated with
800 mg imatinib within the first 5 h after stroke
onset. Currently, imatinib is only available in tablet
form for oral administration. An intravenous form
of imatinib could potentially enhance very early
administration in patients with acute stroke. In
patients with suspected difficulty in swallowing, it
is possible to administer imatinib by nasogastric
tube after dispersion of the tablets in water. A
reduction in the haemorrhage risk with early ima-
tinib treatment would be clinically important
because the risk of bleeding is a serious concern
during the use of IVT and may restrict its use for
some patients. Early high-dose imatinib treatment
also seemed to reduce the occurrence of cerebral
oedema. These observations were consistent with
data from experimental studies in which imatinib
was administered 1 h after the induction of stroke
and thrombolysis with tPA was administered 5 h
after stroke induction [10].
Because of its effects in ischaemic stroke, as shown
in preclinical studies [10, 14] and preliminary
clinical results from our pilot study, the potential
benefit of imatinib in haemorrhagic stroke (intrac-
erebral and subarachnoid haemorrhage) warrants
further preclinical and clinical studies.
This study had several limitations. First, although
evaluations of imaging scans and 3-month out-
comes were blinded, this was an open-label study.
Secondly, the higher frequency of mechanical
thrombectomy in the high-dose group could poten-
tially influence the results. However, the results
were adjusted for mechanical thrombectomy and,
when stratified by thrombectomy, the result was
fairly robust, although the number of patients was
small. Thirdly, a limited number of patients were
enrolled in the study (n = 60).
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In conclusion, imatinib treatment is safe and
tolerable and may reduce neurological disability
in patients with acute ischaemic stroke who
received thrombolysis. The findings of this phase
II study open a new strategy for acute stroke
treatment, complementary to the existing evi-
dence-based treatments, thrombolysis and
thrombectomy. Our findings need confirmation in
a larger trial comparing high-dose imatinib with
placebo. One such trial is in preparation.
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APPENDIX 1
MAIN CRITERIA FOR INTRAVENOUS
THROMBOLYSIS (IVT)
• Clinical diagnosis of acute ischaemic stroke and computed
tomography scan exclusion of haemorrhage
• Symptoms must be distinguishable from an episode of gener-
alized ischaemia (i.e. syncope), seizure or migraine disorder
• Treatment initiated within 4.5 h of stroke onset
Exclusion criteria
• Severe stroke as assessed clinically (e.g. NIHSS score >25)
and/or developing infarct extending into more than one-third
of the middle cerebral artery territory or half of other vascular
territories
• Administration of heparin within 48 h preceding the onset of
stroke with an elevated activated thromboplastin time (aPTT) at
presentation, or corresponding low-molecular weight heparin
• Platelet count below 100 000 mm3. Significant bleeding dis-
order at stroke onset or within the past 6 months, known
haemorrhagic diathesis.
• Patients receiving oral anticoagulants, for example warfarin
sodium (INR >1.7) or direct oral anticoagulation: dabigatran
(Pradaxa, aPTT >40 s), apixaban, rivaroxaban
• History, evidence or suspicion of intracranial haemorrhage
including subarachnoid haemorrhage
• Systolic blood pressure >185 mmHg or diastolic blood pres-
sure >110 mmHg, in spite of repeated doses of i.v. medication
to reduce blood pressure to below these limits
• Any history of central nervous system damage (i.e. neoplasm,
aneurysm, intracranial or spinal surgery) or neurodegenerative
disorder
• Haemorrhagic retinopathy, or other haemorrhagic ophthalmic
conditions
• Patients of childbearing potential, if pregnancy cannot be
excluded by pregnancy test and/or interview
• Major surgery or significant trauma in previous 10 days
(including any trauma associated with current acute
myocardial infarction), recent trauma to head or cranium
APPENDIX 2
MAIN CRITERIA FOR THROMBECTOMY
ACCORDING TO LOCAL GUIDELINES
• Confirmed diagnosis on computed tomography angiography of
persistent occlusion of the proximal middle cerebral artery,
terminal carotid artery or basilar artery consistent with the
clinical symptoms
• NIHSS ≥ 6 or aphasia
• Anticipated life expectancy of at least 6 months
• Initiation of endovascular procedure (defined as start with
groin puncture) within 8 h of symptom onset
Exclusion criteria
• Known significant prestroke disability (mRS ≥ 2)
• Extended early ischaemic changes
• Severe comorbidities such as dementia, terminal illness and
other medical conditions
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APPENDIX 3
INCLUSION AND EXCLUSION CRITERIA
SPECIFIC FOR THE STUDY DRUG IN
ADDITION TO CRITERIA FOR
INTRAVENOUS THROMBOLYSIS (IVT) AND
THROMBECTOMY
Inclusion criteria
• Clinical diagnosis of acute ischaemic stroke causing a
measurable neurological deficit defined as impairment of
language, motor function and cognition, including
dysphasia and neglect, gaze and vision. Ischaemic stroke is
defined as an event characterized by sudden onset of
acute focal neurological deficit, presumed to be caused
by cerebral ischaemia, after CT scan exclusion of haemor-
rhage
• Neurological deficit corresponding to ≥7 points on the National
Institutes of Health Stroke Scale (NIHSS), at the time of
randomization
• Age 18–85 years
• IVT is indicated on clinical grounds and has been initiated
within 4.5 h of stroke onset
• Patients should be randomly assigned to treatment as soon as
possible but not later than 1 h after completion of IVT, or, if
applicable, within 1 h after completion of additional intra-
arterial intervention
• Patients are competent to make a decision and have
provided informed consent with regard to participation in
the study, retrieval and storage of data and follow-up
procedures
Exclusion criteria
• Severe stroke as assessed clinically (e.g. NIHSS > 25) and/or
developing infarct extending into more than one-third of the
middle cerebral artery territory or half of other vascular
territories
• Acute pancreatitis
• Severe hepatic dysfunction, including hepatic failure, cirrhosis,
portal hypertension (oesophageal varices) and active hepatitis
• Ongoing treatment with chemotherapy
• Drugs that may increase the plasma concentration of imatinib:
ketoconazole, itraconazole, erythromycin and clarithromycin
• Drugs that may decrease the plasma concentration of imatinib:
dexamethasone, phenytoin, carbamazepine, rifampicin, phe-
nobarbital, fosphenytoin, primidone and St John’s wort
(Hypericum performatum)
• Contraindications against magnetic resonance imaging
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